|Mr. Joseph D. Dowling||CEO, Sec. & Director||600.6k||N/A||1957|
|Mr. Michael J. Mona III||Co-Founder, COO & Director||548.39k||N/A||1986|
|Mr. Joerg Grasser||Chief Financial Officer||3.43k||N/A||N/A|
|Dr. Joseph Maroon F.A.C.S., M.D.||MD & Director||35k||N/A||1941|
|Dr. Douglas MacKay ND||Sr. VP of Scientific & Regulatory Affairs||N/A||N/A||N/A|
CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.
CV Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.